Session Title: Quick Fire Free Paper 2
Session Date/Time: Thursday 11/09/2014 | 11:00-12:30
Paper Time: 12:00
Venue: Boulevard D
First Author: : S.Soedarman INDONESIA
Co Author(s): : A. Djatikusumo S. Widyawati A. Setiawati
To evaluate the effect of prophylactic nepafenac eye drops on macular thickness changes after phacoemulsification surgery in mild to moderate NPDR patients
KIrana Eye Hospital,RSCM, Jakarta, Indonesia
This study is an open label randomized clinical trial. Thirty-six subjects who met the inclusion criteria underwent phacoemulsification. One group (18 subjects) were given nepafenac 0,1% eye drops and the rest were given placebo; both products were used 3 days before phacoemulsification until 14 days after phacoemulsification. Foveal thickness and total macular volume were measured by SD-OCT before surgery and the fourth week after phacoemulsification. Best corrected visual acuity (BCVA) and degree of inflammation in the anterior chamber were also being assessed.
There was a statistically significant increase foveal thickness in the placebo group 4 weeks after phacoemulsification (paired t-test, p=0,022). In the nepafenac group there was no significant changes in the foveal thickness 4 weeks after phacoemulsification (paired t-test, p = 0,538). One patient in the placebo group had CME. There was an increased in total macular volume, which were statistically significant in both groups (paired t-test, p<0,05) although not significantly different between the two groups (unpaired t-test, p= 0,621). Clinically, percentage degree of inflammation in anterior chamber in placebo group was higher than nepafenac group (38,9% : 5,6%) but not significantly different between 2 groups (Kolmogorov-Smirnov test, p=0,27). Nepafenac group achieved clinically better BCVA than the placebo group 4 weeks after phacoemulsification, although statistically there was no significant difference between two groups (unpaired t-test, p=0,991).
Nepafenac 0,1% eye drops could prevent foveal thickening 4 weeks after phacoemulsification in mild to moderate NPDR patients. Clinically, nepafenac 0,1% eye drops could decrease the risk of inflammation in the anterior chamber, risk of CME, and vision deterioration although did not reach statistically significant.